Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

This study investigated the use of spironolactone in patients with estrogen-dependent cancers, aiming to determine if it is linked to increased cancer recurrence risk, but results are not reported.

This clinical trial reported that Sandalore® 1% significantly reduced hair shedding and increased hair volume and anagen HFs in women with telogen effluvium compared to placebo, supporting its potential use in hair growth treatments.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

In this study, TyroSpheres were used to encapsulate adapalene, increasing its solubility and enhancing skin distribution while reducing irritancy compared to a commercial formulation, indicating promise for acne treatment in ex vivo and in vitro settings.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study developed an inexpensive method to provide initial data on both the photostability and toxicity of pure active principles and their photodegradation products.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.

SesZen-BioTM improves skin health and reduces signs of aging.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study demonstrates that Bazi Bushen capsules may have therapeutic potential against skin photoaging in mice by enhancing NRF2 expression and targeting the KEAP1-NRF2 pathway.

Most clinicians follow discharge guidelines, many lupus patients don't use sunscreen regularly, dithranol is effective for psoriasis, biopsy methods should be based on lesion type, voriconazole may raise skin cancer risk, a new scale can help diagnose female hair loss early, and most melanomas may develop from existing moles.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In a case-series study, researchers reported significant hair regrowth in Alopecia Areata patients after three months of treatment with a topical preparation called Freezia cream, which was developed by specialized medical professionals and approved by the Iraqi Ministry of Health.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.